Luporini G, Clerici M, Montinari F, Fraschini P, Besana C
Boll Ist Sieroter Milan. 1975 Oct 20;54(4):331-6.
The Authors report the preliminary results of a two-step far-reaching investigation carried out on cancer patients to study: 1) the immune conditions of the patients and establish, by a thorough immune monitoring, employing tests of humoral immunity (tetanus toxoid response), of delayed immunity (BCG test, PHA-lymphocyte blastogenesis, MIF release, skin window) and macrophage immunity (skin window), the chemotherapy effects on the immune conditions and the most suitable time to carry out immunotherapy; 2) the immunotherapeutic results which can be obtained with three different immunogens (BCG, C. parvum and ribonucleotides). The results obtained in the first part of the investigations pointed out the usefulness of the tests adopted to follow up the evolution of the immunological reactivity in patients submitted to chemotherapy, while the results of the immunotherapeutic trial show a preliminary character and, at present, do not allow definitive conclusions. Carefully planned and randomized studies are at present under way to establish, more thoroughly, the optimal modalities and the real possibilities of the immunotherapy performed with C. parvum and ribonucleotides in cancer patients.
作者报告了一项针对癌症患者开展的两阶段深入研究的初步结果，该研究旨在：1）研究患者的免疫状况，并通过全面的免疫监测来确定化疗对免疫状况的影响以及进行免疫治疗的最佳时机，免疫监测采用体液免疫测试（破伤风类毒素反应）、迟发型免疫测试（卡介苗试验、植物血凝素淋巴细胞转化、巨噬细胞移动抑制因子释放、皮肤窗试验）以及巨噬细胞免疫测试（皮肤窗试验）；2）研究使用三种不同免疫原（卡介苗、短小棒状杆菌和核糖核苷酸）所能获得的免疫治疗效果。研究第一部分所获结果表明，所采用的测试方法对于跟踪接受化疗患者免疫反应性的演变是有用的，而免疫治疗试验的结果目前具有初步性质，尚无法得出确定性结论。目前正在进行精心规划和随机分组的研究，以更全面地确定使用短小棒状杆菌和核糖核苷酸对癌症患者进行免疫治疗的最佳方式和实际可能性。
